\
&
Contact us
\
&
Contact us
This was 7 years ago
Location ProgrammesThe brokerage event will be of particular interest and relevance to members of the Science with and for Society research community who are looking for networking and funding opportunities within Horizon 2020.
The brokerage event is organized by Sis.net2, the international network of National Contact Points (NCPs) in the field of Science with and for Society in Horizon 2020 in cooperation with the European Commission.
More information about the brokerage event can be found on the dedicated website. Presentations can be found here.
Please note that participation in this event is only possible for those who have already registered and the priority will be given to the participants of bilateral meetings. Your participation is confirmed only when your profile is validated by the organisers. It is allowed the participation of maximum 2 people per organisation.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
